^18F-FDG PET在胰腺癌患者预后评估中的价值  

The value of 18-fluorodeoxyglucose positron emission tomography in prognosis of patients with pancreatic cancer

作　　者：王慧玲[1] 侯宝华[1] 区金锐[1] 

机构地区：[1]广东省人民医院肝胆外科广东省医学科学院,广州510080

出　　处：《中华普通外科杂志》2010年第11期892-894,共3页Chinese Journal of General Surgery

基　　金：广东省科技计划基金资助项目（2007B060401034）

摘　　要：目的 评估18F-FDG PET判断胰腺癌患者预后的价值.方法 回顾性分析54例胰腺癌病例资料.取所有病例PET检查的标准摄取值（standard uptake value,SUV）平均值4为截断点分组,A组22例（SUV≤4）,B组32例（SUV＞4）,分析两组患者的预后.结果 A组1、3年生存率为68.18%、34.91%;B组1、3年生存率为33.61%、11.95%,两组生存率比较差异有统计学意义（P=0.01）;Cox回归分析提示肿瘤分期和SUV是胰腺癌患者预后的独立危险因素.结论 18F-FDG PET在判断胰腺癌预后方面有一定的价值.Objective To evaluate the value of 18F-FDG PET in predicting the prognosis of pancreatic cancer. Methods Fifty-four cases of pancreatic cancer were divided into two groups. Taking standard uptake value（SUV） at 4 as the cut off point, patients （22 cases） with that not more than four were classified into group A, and those （32 cases） with SUV greater than four were into group B. The prognosis of patients by SUV was analyzed statistically. Results There was a statistically significant difference in survival between the two groups （ P =0. 01 ）. The 1-,3-year survival rate was 68. 18% 、34. 91% in group A in those the SUV≤4, and 33.61% 、11.95% in group B（ SUV 〉4）, respectively. Cox proportional hazard model showed that tumor staging and SUV were the significantly independent prognostic factors in patients with pancreatic cancer. Conclusions 18F-FDG PET is of value in predicting the prognosis of patients with pancreatic cancer.

关 键 词：胰腺肿瘤 正电子发射断层显像术 肿瘤分期 

分 类 号：R686[医药卫生—骨科学]